SITE003-0210

SITE003 (CAN) › SITE003-0210

SITE003-0210

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2026-05-09

enrolled

AEs

0

Serious

0

Dropout signal

–

Adverse events

0

No adverse events recorded. New events are triaged from the Safety tab.

Data queries

0

No data queries. Open queries would appear here for this patient.